SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001824293-22-000043
Filing Date
2022-05-25
Accepted
2022-05-25 11:58:24
Documents
6
Period of Report
2022-07-13

Document Format Files

Seq Description Document Type Size
1 PRE 14A vallon-draftxpreliminarypr.htm PRE 14A 460947
2 GRAPHIC dpivallonpharmaceuticalsin.jpg GRAPHIC 190590
3 GRAPHIC dpivallonpharmaceuticalsina.jpg GRAPHIC 406317
4 GRAPHIC image_0a.jpg GRAPHIC 34071
5 GRAPHIC image_1a.jpg GRAPHIC 16454
6 GRAPHIC image_2a.jpg GRAPHIC 3154
  Complete submission text file 0001824293-22-000043.txt   1357595
Mailing Address TWO LOGAN SQUARE 100 N. 18TH STREET, SUITE 300 PHILADELPHIA PA 19103
Business Address TWO LOGAN SQUARE 100 N. 18TH STREET, SUITE 300 PHILADELPHIA PA 19103 (267) 207-3606
Vallon Pharmaceuticals, Inc. (Filer) CIK: 0001824293 (see all company filings)

IRS No.: 824369909 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-40034 | Film No.: 22960875
SIC: 2834 Pharmaceutical Preparations